Net Income

Progyny signals better-than-expected 2025 results on robust member engagement, sparking analyst upgrades and sending its stock soaring ahead of a key conference.

New 2025 data reveals an AI platform is slashing costs, improving chronic disease outcomes, and closing health equity gaps for hundreds of clinicians.

The wellness firm secured a cash infusion by repricing options, a move that provides vital funds for its Zola brand but raises questions about dilution.

Tech consultancy Hylaine hires veteran exec Doug Hautop as President to lead an aggressive plan to scale, targeting Fortune 1000 enterprise clients.

Petco is refinancing $1.5B in debt to extend maturities while reaffirming its financial outlook. Is this a sign of strength or underlying strain?

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

Retailers are losing billions to refund abuse, but new AI tools can spot fraud in real time, protecting revenue without punishing your best customers.

For the 24th straight year, nurses top Gallup's ethics poll, but this enduring trust masks a profession in crisis, battling burnout and staff shortages.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

Biomea Fusion launches a high-stakes 2026 plan, advancing a novel diabetes drug to restore insulin cells and an oral pill to rival obesity giants.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

Interim data suggests LX2020 is well-tolerated and may reduce dangerous arrhythmias by targeting the root cause of PKP2-associated cardiomyopathy.

Backed by Purolator, a massive network expansion by Williams Pharmalogistics aims to reshape Canada's temperature-controlled medical delivery landscape.

Adaptive posted a 55% revenue surge in 2025, fueled by its clonoSEQ cancer test. Now, the firm is charting a clear course to company-wide profitability.

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.